Generalized lipodystrophy
MONDO:0027766Almost complete absence of subcutaneous and/or visceral adipose tissue.
Also known as: complete generalised lipodystrophy, complete generalized lipodystrophy
12 clinical trials for this condition and its sub-types, 8 tagged with Generalized lipodystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Generalized lipodystrophy
-
Congenital generalized lipodystrophy 2 trials · 3 incl. sub-types
5 sub-types
-
Acquired generalized lipodystrophy 0 trials
-
New drug could help rare fat disorder patients
Disease control Recruiting nowThis study tests a new drug called mibavademab for people with generalized lipodystrophy, a rare condition where the body lacks fat tissue. The goal is to see if the drug can improve blood sugar, lower blood fats, and reduce liver fat. About 28 children and adults will take part …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New registry tracks Real-World safety of rare disease drug metreleptin
Disease control Recruiting nowThis registry monitors the safety and effectiveness of metreleptin in up to 100 people with generalized or partial lipodystrophy who are already taking the drug in routine care. Researchers will track serious events like pancreatitis, liver problems, infections, and cancers. The …
Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Rare leptin disorder patients gain access to experimental drug
Disease control Expanded accessThis program provides expanded access to REGN4461 (mibavademab) for people with rare diseases caused by deficient leptin signaling, such as generalized lipodystrophy and monogenic obesity. The drug aims to help control metabolic issues linked to these conditions. Participants rec…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC